Fetus Receives Life-Saving Medication Inside Womb in Medical First
Doctors in the US have treated a fetus with a rapidly progressive congenital disease from inside the womb for the very first time.
Instead of giving medicine to a child with severe neuromuscular complications after they are born, a new case study details how a prospective mother agreed to take the medicine for her developing fetus while she was still pregnant.
A prenatal test had shown that her fetus held two genetic mutations indicating type 1 spinal muscular atrophy (SMA), which usually results in severe muscle weakness and breathing difficulties within six months of birth.
Historically, most children with type 1 SMA die by their second birthday, usually from respiratory failure. However, the child in this study has so far made it to the age of two and a half years with no sign of symptoms.
The parents of the treated child had previously experienced the loss of their baby to spinal muscular atrophy, and when testing showed their most recent fetus also had the progressive neuromuscular disease, they wanted to know if they could start treatments earlier.
For this single case, the FDA approved the early administration of the oral drug risdiplam, brand name Evrysdi, owned by the pharmaceutical company F. Hoffmann-La Roche AG.
Over the years, randomized controlled trials have shown risdiplam to be both safe and effective at treating spinal muscular atrophy in newborns, and the younger the kids are when they start receiving the medicine, the better the outcomes overall.
In the new study, the pregnant mother took a dose of risdiplam each day for six weeks before giving birth. Testing found that the medicine trickled right through her umbilical cord blood and the amniotic fluid bathing her fetus. After birth, it was the infant that was given the daily oral drug, not the mother.
Pediatric neurologist Michelle Farrar, who is working on a minimally invasive gene therapy treatment for SMA in Australia, told Smriti Mallapaty at Nature that the baby girl with SMA "has been effectively treated, with no manifestations of the condition" even 30 months after birth.
In 2020, risdiplam was first approved by the US Food and Drug Administration (FDA) for kids with spinal muscular atrophy, but only over the age of two months.
Recent clinical trials funded by Roche, however, found the majority of children with spinal muscular atrophy treated with risdiplam before six weeks of age could swallow, feed, sit, stand, and walk on their own after two years of treatment. None required permanent ventilation.
Risdiplam works to prevent the degeneration of nerve cells in the brain and body by increasing the concentration of a crucial protein, called survival motor neuron (SMN) protein. Active SMN proteins are lacking in those with genetic mutations that cause spinal muscular atrophy.
"In children with SMA, motor neuron degeneration starts before the onset of symptoms, so time is of the essence if we hope to preserve muscle function," said pediatric neurologist Laurent Servais in a press release for a Roche clinical trial in 2024.
"It's heartening to see that through early intervention with Evrysdi these children have achieved important milestones like sitting, standing, and walking that would typically be unattainable without treatment."
Whether or not the recent case study in the US will inspire and embolden doctors and parents to trial risdiplam at earlier stages of development remains to be seen.
"Results in this single case cannot be generalized but may support the consideration of prenatal risdiplam treatment for SMA identified in utero," write the authors of the correspondence.
The study was published in The New England Journal of Medicine.
There's a Critical Thing We Can All Do to Keep Alzheimer's Symptoms at Bay
Traces of a Nutrient in Brazil Nuts Could Fight Cancer, But Dosage Is Crucial
Tardigrade Protein Could Soon Make Cancer Patients More Radiation Proof
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
32 minutes ago
- Wall Street Journal
A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to prevent HIV—a milestone in the decadeslong fight against a once-devastating disease. For Gilead Sciences GILD -0.28%decrease; red down pointing triangle, the dominant player in HIV treatment, the breakthrough is doing what years of splashy but underwhelming acquisitions failed to achieve: It has Wall Street paying attention again. Since reporting last June that just two annual shots of lenacapavir prevented all HIV infections in a study of women and girls, shares have surged 73%.
Forbes
an hour ago
- Forbes
FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes
AI at the FDA getty The U.S. Food and Drug Administration announced this week that it deployed a generative AI tool called ELSA (Evidence-based Learning System Assistant), across its organization. After a low-profile pilot that delivered measurable gains, the system is now in use by staff across the agency, several weeks ahead of its original schedule. Dr. Marty Makary, the FDA's commissioner, shared a major outcome. A review task that once took two or three days now takes six minutes. 'Today, we met our goal ahead of schedule and under budget,' said Makary. 'What took one scientific reviewer two to three days [before] The FDA has thousands of reviewers, analysts, and inspectors who deal with massive volumes of unstructured data such as clinical trial documents, safety reports, inspection records. Automating any meaningful portion of that stack creates outsized returns. ELSA helps FDA teams speed up several essential tasks. Staff are already using it to summarize adverse event data for safety assessments, compare drug labels, generate basic code for nonclinical database setup, and identify priority sites for inspections, among other tasks. This last item, using data to rank where inspectors should go, could have a real-world impact on how the FDA oversees the drug and food supply chain and impacts on how the FDA delivers its services. Importantly, however, the tool isn't making autonomous decisions without a human in the loop. The system prepares information so that experts can decide faster. It cuts through the routine, not the judgment. One of the biggest questions about AI systems in the public sector revolves around the use of data and third party AI systems. Makary addressed this directly by saying that 'All information stays within the agency. The AI models are not being trained on data submitted by the industry.' That's a sharp contrast to the AI approaches being taken in the private sector, where many large language models have faced criticism over training on proprietary or user-submitted content. In the enterprise world, this has created mounting demand for "air-gapped" AI solutions that keep data locked inside the company. That makes the FDA's model different from many corporate tools, which often rely on open or external data sources. The agency isn't building a public-facing product. It's building a controlled internal system, one that helps it do its job better. Federal departments have been slow to move past AI experimentation. The Department of Veterans Affairs has started testing predictive tools to manage appointments. The SEC has explored market surveillance AI for years. But few have pushed into full and widespread production. The federal government has thousands of employees processing huge volumes of information, most of it unstructured sitting in documents, files, and even paper. That means AI is being focused most on operational and process-oriented activities. It's shaping up to be a key piece of how agencies process data, make recommendations, and act. Makary put it simply that ELSA is just the beginning for AI adoption within the FDA. 'Today's rollout of ELSA will be the first of many initiatives to come,' he said. 'This is how we'll better serve the American people.'
Yahoo
an hour ago
- Yahoo
FDA Announces Recall on Popular Aldi Product for Undeclared Life-Threatening Allergen
Select boxes of a popular Casa Mamita product sold at Aldi stores in 13 states have been recalled, according to the U.S. Food & Drug Administration (FDA). Aldi's Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream have been recalled because they may contain an undeclared milk allergen. Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream sold at Aldi stores in Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, and Tennessee are impacted by this recall. The recalled product was sold in a 7.05-ounce cardboard box and has the lot number 01425 and 'Best If Used By' date of July 14, 2025, on the label. You can find product images on the FDA's site. No other Casa Mamita or Aldi products are impacted by this recall. The churro bites were recalled because the product contains milk, but the allergy warning for milk is not printed on the box, which the FDA requires. Camerican International, the maker of the recalled Casa Mamita product, has identified the issue as due to a 'temporary breakdown' in the processing and packaging, which has since been resolved. If you have a milk allergy, you should not consume the product as it can cause serious or life-threatening reactions for those with milk allergies or intolerances. Instead, you can throw it away or return it to your Aldi store for a full refund. As of this writing, there have not been any reports of allergic reactions or illnesses caused by consuming the Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. If you don't have a milk allergy, you do not have to do anything regarding this recall. The product was recalled due to a labeling error and not because it is inherently unsafe to eat. For any questions regarding the recall, you can contact Camerican International directly at 1-201-587-0101 or fsqaincidents@ Read the original article on ALLRECIPES
